{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:04:27Z","timestamp":1784801067283,"version":"3.55.0"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background and Objectives: Hyperphosphatemia is a key component of chronic kidney disease-mineral and bone disorder and is associated with higher rates of cardiovascular events and mortality in patients undergoing dialysis. Phosphate binders are essential for phosphorus reduction, and their evaluation relies on several factors, such as chemical composition, binding capacity, and safety profile. Unfortunately, long-term management is hindered by high pill burden and poor adherence. Magnesium phosphate binders have proven effectiveness in reducing phosphate levels. Nevertheless, despite their efficacy, they are not widely used in clinical settings because of concerns related to their use. This study assessed the efficacy of low-dose magnesium carbonate as a phosphate binder in patients undergoing chronic dialysis, focusing on its biochemical control, tolerability, and cost-effectiveness. Materials and Methods: A prospective observational study was conducted on 54 hemodialysis patients with end-stage renal disease at a single dialysis center. Patients were taking either 250 mg magnesium carbonate or 2400 mg sevelamer carbonate for 3 months. Results: Both groups showed decreased phosphorus levels, with a 14.2% significant reduction in the magnesium carbonate group (p &lt; 0.001) and a 5.1% reduction in the sevelamer carbonate group. At the end of the study, no significant differences were observed between the groups (p = 0.682). In the magnesium carbonate group at month 3, compared to baseline, no significant differences were detected in other laboratory parameters reflecting calcium\u2013phosphorus metabolism (Ca\u2014p = 0.681, PTH\u2014p = 0.126). Simultaneously, good compliance without clinically relevant gastrointestinal side effects was observed, including the absence of clinically significant hypermagnesemia. Conclusions: The phosphorus-lowering potential of low-dose magnesium carbonate is non-inferior to that of low-dose sevelamer carbonate. However, its favorable safety profile, low incidence of adverse effects, and cost-effectiveness make it a promising option in clinical practice, further highlighting the need for better recognition by physicians.<\/jats:p>","DOI":"10.3390\/life16071213","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:01:28Z","timestamp":1784768488000},"page":"1213","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evaluation of Low-Dose Magnesium Carbonate as a Phosphate Binder in Chronic Hemodialysis Patients"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3076-770X","authenticated-orcid":false,"given":"Valeri","family":"Tzekov","sequence":"first","affiliation":[{"name":"Second Department of Internal Diseases, Section of Nephrology, Medical University of Plovdiv, 15A Vasil Aprilov Blvd, 4002 Plovdiv, Bulgaria"},{"name":"First Dialysis Services Bulgaria\u2014Dialysis Center, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Kostadinova","sequence":"additional","affiliation":[{"name":"First Dialysis Services Bulgaria\u2014Dialysis Center, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7582-9729","authenticated-orcid":false,"given":"Elizabet","family":"Artinyan","sequence":"additional","affiliation":[{"name":"First Dialysis Services Bulgaria\u2014Dialysis Center, 4002 Plovdiv, Bulgaria"},{"name":"Clinic of Nephrology, University Multiprofile Hospital for Active Treatment \u201cSv. Georgi\u201d, Plovdiv, 15A Vasil Aprilov Blvd, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-6323","authenticated-orcid":false,"given":"Rumyana","family":"Stoyanova","sequence":"additional","affiliation":[{"name":"Department of Health Management and Health Economics, Faculty of Public Health, Medical University of Plovdiv, 15A Vasil Aprilov Blvd, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8755-349X","authenticated-orcid":false,"given":"Evelina","family":"Valcheva","sequence":"additional","affiliation":[{"name":"Clinic of Nephrology, University Multiprofile Hospital for Active Treatment \u201cSv. Georgi\u201d, Plovdiv, 15A Vasil Aprilov Blvd, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-9454","authenticated-orcid":false,"given":"Nikolay","family":"Dimov","sequence":"additional","affiliation":[{"name":"Second Department of Internal Diseases, Section of Nephrology, Medical University of Plovdiv, 15A Vasil Aprilov Blvd, 4002 Plovdiv, Bulgaria"},{"name":"First Dialysis Services Bulgaria\u2014Dialysis Center, 4002 Plovdiv, Bulgaria"},{"name":"Clinic of Nephrology, University Multiprofile Hospital for Active Treatment \u201cSv. Georgi\u201d, Plovdiv, 15A Vasil Aprilov Blvd, 4002 Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Michigami, T., and Ozono, K. (2019). Roles of phosphate in skeleton. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00180"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ckj\/sfae431","article-title":"Pathophysiology of chronic kidney disease\u2013mineral bone disorder (CKD-MBD): From adaptive to maladaptive mineral homeostasis","volume":"18","author":"Salera","year":"2025","journal-title":"Clin. Kidney J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.ackd.2016.03.008","article-title":"CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What we know today?","volume":"23","author":"Melamed","year":"2016","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.15537\/smj.2015.1.9843","article-title":"Hyperphosphatemia","volume":"36","author":"Askar","year":"2015","journal-title":"Saudi Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhou, C., Shi, Z., Ouyang, N., and Ruan, X. (2021). Hyperphosphatemia and cardiovascular disease. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.644363"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18773\/austprescr.2017.002","article-title":"Phosphate binders in patients with chronic kidney disease","volume":"40","author":"Chan","year":"2017","journal-title":"Aust. Prescr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ekir.2022.01.1055","article-title":"Past, present, and future of phosphate management","volume":"7","author":"Doshi","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3949\/ccjm.85a.17054","article-title":"Phosphorus binders: The new and the old, and how to choose","volume":"85","author":"Sekar","year":"2018","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/ckj\/sfu139","article-title":"Iron-based phosphate binders: Do they offer advantages over currently available phosphate binders?","volume":"8","author":"Negri","year":"2014","journal-title":"Clin. Kidney J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.12968\/jorn.2013.5.1.31","article-title":"What are phosphate binders and how do they work?","volume":"5","author":"Akinlade","year":"2013","journal-title":"J. Ren. Nurs."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/IJNRD.S78040","article-title":"Phosphate binders for the treatment of chronic kidney disease: Role of iron oxyhydroxide","volume":"9","author":"Cernaro","year":"2016","journal-title":"Int. J. Nephrol. Renov. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"KDIGO Executive Committee (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1053\/j.ajkd.2017.07.019","article-title":"KDOQI US commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD)","volume":"70","author":"Isakova","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/ndt\/gfab205","article-title":"How to evaluate phosphate control in patients on dialysis","volume":"37","author":"Martin","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1093\/ndt\/gft244","article-title":"Phosphate control in end-stage renal disease: Barriers and opportunities","volume":"28","author":"Waheed","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2215\/CJN.13091216","article-title":"Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders","volume":"12","author":"Komaba","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MNH.0b013e32836214d4","article-title":"Use of phosphate binders in chronic kidney disease","volume":"22","author":"Ketteler","year":"2013","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","article-title":"Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: A controlled randomized study (CALMAG study) assessing efficacy and tolerability","volume":"25","author":"Leidig","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3747\/pdi.2013.00129","article-title":"MgCaCO3 versus CaCO3 in peritoneal dialysis patients\u2014A cross-over pilot trial","volume":"35","author":"Evsanaa","year":"2014","journal-title":"Perit. Dial. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2215\/CJN.02630608","article-title":"Iron-Magnesium hydroxycarbonate (Fermagate)","volume":"4","author":"McIntyre","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wang, C., Liu, X., Zhou, Y., Li, S., Chen, Y., Wang, Y., and Lou, T. (2015). New conclusions regarding comparison of sevelamer and Calcium-Based phosphate binders in Coronary-Artery calcification for dialysis patients: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133938"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1053\/j.jrn.2007.08.005","article-title":"Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: A pilot study","volume":"17","author":"Spiegel","year":"2007","journal-title":"J. Ren. Nutr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfw312","article-title":"The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"32","author":"Habbous","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/ndt\/14.12.2907","article-title":"Long-term effects of sevelamer hydrochloride on the calcium \u00d7 phosphate product and lipid profile of haemodialysis patients","volume":"14","author":"Chertow","year":"1999","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000343397","article-title":"Emerging effects of sevelamer in chronic kidney disease","volume":"37","author":"Ikee","year":"2013","journal-title":"Kidney Blood Press. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11255-007-9300-0","article-title":"Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial","volume":"40","author":"Tzanakis","year":"2008","journal-title":"Int. Urol. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ki.1996.22","article-title":"Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study","volume":"49","author":"Delmez","year":"1996","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/cts.13151","article-title":"Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease","volume":"15","author":"Mason","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"c259","DOI":"10.1159\/000313484","article-title":"Meta-Analysis Comparing sevelamer and Calcium-Based phosphate binders on cardiovascular calcification in hemodialysis patients","volume":"115","author":"Zhang","year":"2010","journal-title":"Nephron Clin. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2210230","DOI":"10.1080\/0886022X.2023.2210230","article-title":"Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients","volume":"45","author":"Zeng","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101046","DOI":"10.1016\/j.xkme.2025.101046","article-title":"Paradoxical inadequate parathyroid hormone secretion secondary to severe hypomagnesemia: A review of the literature","volume":"7","author":"Albert","year":"2025","journal-title":"Kidney Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3934\/publichealth.2016.2.329","article-title":"Magnesium: Nutrition and homoeostasis","volume":"3","author":"Vormann","year":"2016","journal-title":"AIMS Public Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2215\/CJN.07930717","article-title":"Anion gap as a determinant of ionized fraction of divalent cations in hemodialysis patients","volume":"13","author":"Sakaguchi","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Aal-Hamad, A.H., Al-Alawi, A.M., Kashoub, M.S., and Falhammar, H. (2023). Hypermagnesemia in clinical practice. Medicina, 59.","DOI":"10.3390\/medicina59071190"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.jrn.2011.03.001","article-title":"Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease","volume":"22","author":"Wyskida","year":"2011","journal-title":"J. Ren. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Karamanidou, C., Clatworthy, J., Weinman, J., and Horne, R. (2008). A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol., 9.","DOI":"10.1186\/1471-2369-9-2"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.15537\/smj.2020.10.25381","article-title":"Phosphate binders usage, patients\u2019 knowledge, and adherence","volume":"41","author":"Aleidi","year":"2020","journal-title":"Saudi Med. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/IJNRD.S41626","article-title":"Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients","volume":"7","author":"Ossareh","year":"2014","journal-title":"Int. J. Nephrol. Renov. Dis."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:32:47Z","timestamp":1784799167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["life16071213"],"URL":"https:\/\/doi.org\/10.3390\/life16071213","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}